Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Serono Austria GMBH
EVIDENCE-Umstellungsstudie (22 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 15: MRT-Ergebnisse  - Rebif Abb. 16: MRT-Ergebnisse - Umstellung - Avonex - Rebif Abb. 17: EVIDENCE-Umstellung Aktuelles Bild - Abb. 18: Nebenwirkungen Abb. 19: Umstellung - Behandlungsabbrüche Abb. 20: Risiko/Nutzen-Analyse Abb. 21: Schlußfolgerungen Zum letzten Bild
Abbildung 18: Nebenwirkungen
Addresses most common IFN-related adverse events. Pre-T is pre-Transition rate Post-T is post-Transition rate Points to note: new onset events very uncommon on 44/44 indicating that most patients who develop IFN-related Aes do so early on; increase in ISR for 30/44 is expected based on change in route of administration; numbers of new LFT and WBC events is consistent with dose effect of IFN on these events; number of new FLS is quite low compared to initiation of 30mcg though still greater than new FLS for 44/44 group.
 
Nebenwirkungen
Vorheriges Bild Nächstes Bild   


Abbildung 18: Nebenwirkungen
Addresses most common IFN-related adverse events. Pre-T is pre-Transition rate Post-T is post-Transition rate Points to note: new onset events very uncommon on 44/44 indicating that most patients who develop IFN-related Aes do so early on; increase in ISR for 30/44 is expected based on change in route of administration; numbers of new LFT and WBC events is consistent with dose effect of IFN on these events; number of new FLS is quite low compared to initiation of 30mcg though still greater than new FLS for 44/44 group.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung